Lung cancer chemoprevention: current status and future prospects

Lung cancer is the leading cause of cancer death worldwide, making it an attractive disease for chemoprevention. Although avoidance of tobacco use and smoking cessation will have the greatest impact on lung cancer development, chemoprevention could prove to be very effective, particularly in former smokers. Chemoprevention is the use of agents to reverse or inhibit carcinogenesis and has been successfully applied to other common malignancies. Despite prior studies in lung cancer chemoprevention failing to identify effective agents, we now have the ability to identify high-risk populations, and our understanding of lung tumour and premalignant biology continues to advance. There are distinct histological lesions that can be reproducibly graded as precursors of non-small-cell lung cancer and similar precursor lesions exist for adenocarcinoma. These premalignant lesions are being targeted by chemopreventive agents in current trials and will continue to be studied in the future. In addition, biomarkers that predict risk and response to targeted agents are being investigated and validated. In this Review, we discuss the principles of chemoprevention, data from preclinical models, completed clinical trials and observational studies, and describe new treatments for novel targeted pathways and future chemopreventive efforts.

[1]  P. Rothwell,et al.  Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. , 2012, The Lancet. Oncology.

[2]  Y. Miller,et al.  A Randomized Phase II Chemoprevention Trial of 13-CIS Retinoic Acid with Or without α Tocopherol or Observation in Subjects at High Risk for Lung Cancer , 2009, Cancer Prevention Research.

[3]  C. Coulson.  Electronic configuration and carcinogenesis. , 1953, Advances in cancer research.

[4]  J. Y. Park,et al.  Aspirin use and risk for lung cancer: a meta-analysis. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Raphael A Nemenoff,et al.  Tumorigenesis and Neoplastic Progression Analysis of Orthologous Gene Expression between Human Pulmonary Adenocarcinoma and a Carcinogen-Induced Murine Model , 2010 .

[6]  S. Lippman,et al.  Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. , 2001, Journal of the National Cancer Institute.

[7]  David B. Holiday,et al.  Beta-Carotene, vitamin A, and lung cancer chemoprevention: results of an intermediate endpoint study. , 1995, The American journal of clinical nutrition.

[8]  M. Spitz,et al.  An Expanded Risk Prediction Model for Lung Cancer , 2008, Cancer Prevention Research.

[9]  J. Siegfried,et al.  Estrogen receptor signaling in lung cancer. , 2009, Seminars in oncology.

[10]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[11]  J. Mulshine,et al.  Topical delivery of 13-cis-retinoic acid by inhalation up-regulates expression of rodent lung but not liver retinoic acid receptors. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  J. Siegfried,et al.  Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens. , 2012, Carcinogenesis.

[13]  R. Memmott,et al.  Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis , 2010, Cancer Prevention Research.

[14]  D. Slaughter,et al.  “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin , 1953, Cancer.

[15]  E. White,et al.  Long-term use of supplemental multivitamins, vitamin C, vitamin E, and folate does not reduce the risk of lung cancer. , 2008, American journal of respiratory and critical care medicine.

[16]  T. Willson,et al.  Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Y. Miller,et al.  Vascular Endothelial Growth Factor Receptor 2–Targeted Chemoprevention of Murine Lung Tumors , 2010, Cancer Prevention Research.

[18]  L. Booker,et al.  The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial. , 1992, British Journal of Cancer.

[19]  P. Metcalf,et al.  COPD prevalence is increased in lung cancer, independent of age, sex and smoking history , 2009, European Respiratory Journal.

[20]  Xianglin L. Du,et al.  Menopausal Hormone Therapy Does Not Influence Lung Cancer Risk: Results from the California Teachers Study , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[21]  V. Keshamouni,et al.  Peroxisome proliferator-activated receptor-γ activation inhibits tumor progression in non-small-cell lung cancer , 2004, Oncogene.

[22]  B. Gillespie,et al.  Patterns of absolute risk of lung cancer mortality in former smokers. , 1993, Journal of the National Cancer Institute.

[23]  Karen A Gelmon,et al.  Exemestane for breast-cancer prevention in postmenopausal women. , 2011, The New England journal of medicine.

[24]  Gang Liu,et al.  Effects of cigarette smoke on the human airway epithelial cell transcriptome. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[25]  E. Smit,et al.  CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone. , 2008, Lung cancer.

[26]  G. Omenn,et al.  Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. , 1996, The New England journal of medicine.

[27]  Loyda B. Mendez,et al.  Inhaled aerosol particle dosimetry in mice: A review , 2010, Inhalation toxicology.

[28]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[29]  H. Varmus,et al.  Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. , 2001, Genes & development.

[30]  S. Jick,et al.  Metformin does not alter the risk of lung cancer: a case-control analysis. , 2012, Lung cancer.

[31]  P. Snijders,et al.  DNA copy number alterations in endobronchial squamous metaplastic lesions predict lung cancer. , 2011, American journal of respiratory and critical care medicine.

[32]  R. Doll,et al.  Randomised trial of prophylactic daily aspirin in British male doctors , 1988, British medical journal.

[33]  M. Sporn.  Approaches to prevention of epithelial cancer during the preneoplastic period. , 1976, Cancer research.

[34]  E. Siegel,et al.  Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Y. Miller,et al.  Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. , 2002, Cancer research.

[36]  Kyung Soo Lee,et al.  Natural history of pure ground-glass opacity lung nodules detected by low-dose CT scan. , 2013, Chest.

[37]  John D. Minna,et al.  Divergent Genomic and Epigenomic Landscapes of Lung Cancer Subtypes Underscore the Selection of Different Oncogenic Pathways during Tumor Development , 2011, PloS one.

[38]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[39]  H. Witschi.  Tobacco smoke as a mouse lung carcinogen. , 1998, Experimental lung research.

[40]  S. Lam,et al.  A Randomized Phase IIb Trial of Pulmicort Turbuhaler (Budesonide) in People with Dysplasia of the Bronchial Epithelium , 2004, Clinical Cancer Research.

[41]  A. McCullough.  Comprehensive genomic characterization of squamous cell lung cancers , 2013 .

[42]  V. Steele,et al.  Chemoprevention of pulmonary carcinogenesis by brief exposures to aerosolized budesonide or beclomethasone dipropionate and by the combination of aerosolized budesonide and dietary myo-inositol. , 2000, Carcinogenesis.

[43]  T. Key.  Fruit and vegetables and cancer risk , 2010, British Journal of Cancer.

[44]  Final report on the aspirin component of the ongoing Physicians' Health Study. , 1989, The New England journal of medicine.

[45]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[46]  G. Goodman,et al.  A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC). , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  S. Mirvish.  The carcinogenic action and metabolism of urethan and N-hydroxyurethan. , 1968, Advances in cancer research.

[48]  M. Spitz,et al.  Lung carcinoma in former smokers , 1996, Cancer.

[49]  Hiromasa Yamamoto,et al.  Sequential Molecular Changes during Multistage Pathogenesis of Small Peripheral Adenocarcinomas of the Lung , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[50]  J. Vane.  Prostacyclin: a hormone with a therapeutic potential. The Sir Henry Dale Lecture for 1981. , 1982, The Journal of endocrinology.

[51]  P. Lønning,et al.  Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study , 2003, BMJ : British Medical Journal.

[52]  Calum MacAulay,et al.  A Phase I Study of myo-Inositol for Lung Cancer Chemoprevention , 2006, Cancer Epidemiology Biomarkers & Prevention.

[53]  S. Ferretti,et al.  Randomized Phase II Trial of Inhaled Budesonide versus Placebo in High-Risk Individuals with CT Screen–Detected Lung Nodules , 2010, Cancer Prevention Research.

[54]  J. Connett,et al.  Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[55]  Y. Miller,et al.  Oral Iloprost Improves Endobronchial Dysplasia in Former Smokers , 2011, Cancer Prevention Research.

[56]  A. Nicholson,et al.  Reproducibility of the WHO/IASLC grading system for pre‐invasive squamous lesions of the bronchus: a study of inter‐observer and intra‐observer variation , 2001, Histopathology.

[57]  S. Belinsky,et al.  Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model. , 2007, Carcinogenesis.

[58]  T. Byers,et al.  Bronchial Epithelial Ki-67 Index Is Related to Histology, Smoking, and Gender, but Not Lung Cancer or Chronic Obstructive Pulmonary Disease , 2007, Cancer Epidemiology Biomarkers & Prevention.

[59]  T. Jacks,et al.  Somatic activation of the K-ras oncogene causes early onset lung cancer in mice , 2001, Nature.

[60]  S. Lippman,et al.  N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[61]  A. Ferrara,et al.  Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes , 2011, Diabetes Care.

[62]  G Block,et al.  The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study in Finland. , 2009, Nutrition reviews.

[63]  S. Malkoski,et al.  N-nitroso-tris-chloroethylurea Induces Premalignant Squamous Dysplasia in Mice , 2011, Cancer Prevention Research.

[64]  J. Manson,et al.  Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. , 1996, The New England journal of medicine.

[65]  M. Sporn,et al.  The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. , 2007, Cancer research.

[66]  Unopposed estrogen and estrogen plus progestin menopausal hormone therapy and lung cancer risk in the NIH–AARP Diet and Health Study Cohort , 2012, Cancer Causes & Control.

[67]  S. Lippman,et al.  Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  R. DuBois,et al.  Eicosanoids and cancer , 2010, Nature Reviews Cancer.

[69]  Y. Miller,et al.  Lung cancer: genetics of risk and advances in chemoprevention , 2005, Current opinion in pulmonary medicine.

[70]  J. Minna,et al.  Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma , 1999, Oncogene.

[71]  Meng Xu,et al.  The effect of metformin and thiazolidinedione use on lung cancer in diabetics , 2012, BMC Cancer.

[72]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[73]  Yan Lu,et al.  Chemopreventive Effects of Pioglitazone on Chemically Induced Lung Carcinogenesis in Mice , 2010, Molecular Cancer Therapeutics.

[74]  J. Engelman,et al.  Chemoprevention Meets Glucose Control , 2010, Cancer Prevention Research.

[75]  Ching-Chu Chen,et al.  Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan. , 2012, Clinical lung cancer.

[76]  B. Johnson,et al.  Second lung cancers in patients after treatment for an initial lung cancer. , 1998, Journal of the National Cancer Institute.

[77]  P. Rothwell,et al.  Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials , 2011, The Lancet.

[78]  S. Narumiya,et al.  Prostacyclin Prevents Murine Lung Cancer Independent of the Membrane Receptor by Activation of Peroxisomal Proliferator–Activated Receptor γ , 2008, Cancer Prevention Research.

[79]  H. Haick,et al.  Non-invasive Breath Analysis of Pulmonary Nodules , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[80]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[81]  O. Dalesio,et al.  EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. , 2000, Journal of the National Cancer Institute.

[82]  J. Maurer.  Inhaled Corticosteroids and Risk of Lung Cancer among Patients with Chronic Obstructive Pulmonary Disease , 2008 .

[83]  S. Lam,et al.  Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer. , 2008, American journal of respiratory and critical care medicine.

[84]  R. Caprioli,et al.  Lung cancer diagnosis from proteomic analysis of preinvasive lesions. , 2011, Cancer research.

[85]  L. Tanoue.  Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer , 2009 .

[86]  C. Morrison,et al.  A Chemically Induced Model for Squamous Cell Carcinoma of the Lung in Mice , 2004, Cancer Research.

[87]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[88]  J. DeGregori,et al.  Using functional genomics to overcome therapeutic resistance in hematological malignancies , 2013, Immunologic research.

[89]  Prabhat Jha,et al.  21st-century hazards of smoking and benefits of cessation in the United States. , 2013, The New England journal of medicine.

[90]  S. Suissa,et al.  The Use of Metformin and the Incidence of Lung Cancer in Patients With Type 2 Diabetes , 2012, Diabetes Care.

[91]  Stephen A. Williams,et al.  Unlocking Biomarker Discovery: Large Scale Application of Aptamer Proteomic Technology for Early Detection of Lung Cancer , 2010, PloS one.

[92]  Y. Miller,et al.  Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[93]  A. Malkinson,et al.  Butylated hydroxytoluene exposure is necessary to induce lung tumors in BALB mice treated with 3-methylcholanthrene. , 1997, Cancer research.

[94]  T. Rabbitts,et al.  Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer. , 2010, American journal of respiratory and critical care medicine.

[95]  A. Malkinson,et al.  Indomethacin reduces lung adenoma number in A/J mice. , 2001, Anticancer research.

[96]  Edward S. Kim,et al.  Biological Activity of Celecoxib in the Bronchial Epithelium of Current and Former Smokers , 2010, Cancer Prevention Research.

[97]  Adam M. Gustafson,et al.  Airway PI3K Pathway Activation Is an Early and Reversible Event in Lung Cancer Development , 2010, Science Translational Medicine.

[98]  S. Lam,et al.  A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. , 2002, Journal of the National Cancer Institute.

[99]  P. Lange,et al.  Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial , 1999, The Lancet.

[100]  J. Manson,et al.  Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. , 2005, JAMA.

[101]  J. Minna,et al.  EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. , 2005, Cancer research.

[102]  C. la Vecchia,et al.  Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. , 2012, The oncologist.

[103]  Y. Miller,et al.  Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. , 1997, The Journal of clinical investigation.

[104]  Matthew B Schabath,et al.  A risk model for prediction of lung cancer. , 2007, Journal of the National Cancer Institute.

[105]  Tetsuro Tsujimoto,et al.  Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis , 2012, PloS one.

[106]  L. Thiberville,et al.  Molecular predictive factors for progression of high-grade preinvasive bronchial lesions. , 2008, American journal of respiratory and critical care medicine.

[107]  R. Elashoff,et al.  Lung Cancer Chemoprevention with Celecoxib in Former Smokers , 2011, Cancer Prevention Research.

[108]  J. Manson,et al.  Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. , 2010, Journal of the National Cancer Institute.

[109]  Yan Lu,et al.  Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J mice , 2011, Molecular carcinogenesis.

[110]  M R Cullen,et al.  Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. , 1996, Journal of the National Cancer Institute.

[111]  A. Nicholson,et al.  Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[112]  L. Dwyer-Nield,et al.  Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. , 2002, Carcinogenesis.

[113]  J. Verdebout,et al.  Epidermal growth factor receptor expression in pre-invasive and early invasive bronchial lesions , 2003, European Respiratory Journal.

[114]  N. Anthonisen,et al.  The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial , 2005 .

[115]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[116]  M. Sporn,et al.  The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis , 2008, Molecular Cancer Therapeutics.

[117]  E. Dmitrovsky,et al.  Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia and coexpression precedes squamous cell carcinoma development. , 1995, Cancer research.

[118]  Y. Miller,et al.  Alveolar Hypoxia Promotes Murine Lung Tumor Growth through a VEGFR-2/EGFR-Dependent Mechanism , 2012, Cancer Prevention Research.

[119]  D. Heimburger,et al.  Improvement in bronchial squamous metaplasia in smokers treated with folate and vitamin B12. Report of a preliminary randomized, double-blind intervention trial. , 1988, JAMA.

[120]  M. Sporn,et al.  Synthetic Oleanane Triterpenoids: Multifunctional Drugs with a Broad Range of Applications for Prevention and Treatment of Chronic Disease , 2012, Pharmacological Reviews.

[121]  A. Potti,et al.  Hormone replacement therapy is associated with decreased survival in women with lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  C. Begg,et al.  Variations in lung cancer risk among smokers. , 2003, Journal of the National Cancer Institute.